FDA Peptide Compounding Update
FDA Peptide Compounding Update
July 2026 PCAC Meeting Results and What Comes Next
Yoon Hang Kim, MD, MPH
Board-Certified Preventive Medicine | Integrative & Functional Medicine
Last updated: September 17, 2026
⚠ DISCLAIMER: This article is for educational purposes only and is based on publicly available regulatory documents. It is not legal advice, medical advice, or a recommendation to use any peptide substance. Physicians should consult a licensed healthcare attorney before making clinical or business decisions based on evolving FDA guidance.
Executive Summary
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee met at the agency's White Oak Campus in Silver Spring, Maryland and voted on seven peptides for potential inclusion on the Section 503A Bulk Drug Substances List. The committee recommended six of the seven for inclusion — voting contrary to FDA staff recommendations on every one of those six. This is a significant development. It is also widely misunderstood.
The PCAC vote is advisory. It is not rulemaking and does not itself establish compounding eligibility or grant FDA approval. Adding these substances to the 503A Bulks List would require FDA rulemaking. Legal commentators have estimated that the process could take approximately 12–24 months, but that estimate is not an FDA commitment or a guaranteed availability date.
This article breaks down what happened, what it means for clinicians, what it does not mean, and what to watch for next.
Regulatory Timeline: How We Got Here
September 29, 2023 — The Category 2 Freeze
The FDA moved more than a dozen peptides to Category 2 under its interim 503A compounding policy, designating them as substances that "raise significant safety concerns." This placed the substances outside the Category 1 enforcement-discretion policy. Stakeholders and legal commentators argued that restricting access through supervised channels redirected demand toward unregulated, research-use-only vendors — though the magnitude of that effect has not been independently established.
February 27, 2026 — HHS Signals a Reversal
HHS Secretary Robert F. Kennedy Jr. publicly announced that the administration would take steps to make approximately 14 of the restricted peptides more accessible through lawful compounding channels. He described the 2023 restrictions as having been done "illegally" under the prior administration. Important context: a cabinet statement is not a rule, and it did not change any peptide's legal status on its own.
April 15–23, 2026 — Category 2 Removals
The FDA published a Federal Register notice announcing the removal of 12 peptides from Category 2 after their nominations were withdrawn. That administrative change removed the enforcement-policy designation that had signaled FDA's safety concerns — but it did not establish eligibility for compounding under Section 503A or place the substances within Category 1's interim enforcement-discretion policy. Category 2 removal and 503A Bulks List inclusion are two separate regulatory actions that should not be conflated.
July 23–24, 2026 — The PCAC Vote
The advisory committee evaluated seven peptides across two days and recommended six for the 503A Bulks List. FDA staff had recommended against all seven. The committee voted contrary to staff recommendations on all six favorable votes — an outcome McDermott Will & Schulte described as unusual, noting that the FDA has historically rarely diverged from PCAC recommendations.
A note on committee composition: Prior to June 2026, the PCAC had only three standing voting members against an authorized slate of twelve. On June 29, 2026, the FDA announced a reconstituted committee that included at least eight new members, some with ties to peptide businesses or clinics. Several legal observers — including Orrick, Herrington & Sutcliffe — noted before the meeting that the reconstituted composition made favorable recommendations more likely. This context does not invalidate the vote, but it is relevant to understanding the outcome.
PCAC Vote Results: July 23–24, 2026
Peptide | Reviewed Indication(s) | Vote | Result |
BPC-157 | Ulcerative colitis | 8-6 (1 abst.) | RECOMMENDED |
TB-500 | Wound healing | 8-6 (1 abst.) | RECOMMENDED |
KPV | Wound healing, inflammatory conditions | 8-6 (1 abst.) | RECOMMENDED |
MOTS-c | Obesity, osteoporosis | 7-5 (2 abst.) | RECOMMENDED |
Semax | Cerebral ischemia, migraine, trigeminal neuralgia | 8-5 (1 abst.) | RECOMMENDED |
Epitalon | Insomnia | 7-4 (1 abst.) | RECOMMENDED |
Emideltide (DSIP) | Opioid withdrawal, insomnia, narcolepsy | 6-7 (1 abst.) | NOT RECOMMENDED |
Sources: McDermott Will & Schulte meeting report (July 27, 2026); Clinical Peptide post-hearing analysis (July 25, 2026); FDA meeting agenda and briefing documents. Docket: FDA-2025-N-6895.
The Evidence Gap: What the Briefing Documents Actually Said
FDA briefing documents, published before the hearing, recommended against listing all seven peptides. The reasons varied by compound but centered on recurring themes: insufficient human clinical safety and efficacy data, concerns about immunogenicity and aggregation common to synthetic peptides, and — for some substances — existing approved therapies already covering the nominated indications.
Specifically:
BPC-157 has extensive animal research but limited human clinical evidence. No large-scale randomized controlled trials in humans have been completed.
TB-500 (N-acetylated thymosin beta-4 fragment, Ac-LKKTETQ): FDA reported no direct human administration studies of this specific fragment. TB-500 is a synthetic 7-amino-acid fragment corresponding to residues 17–23 of the 43-amino-acid thymosin beta-4 molecule. Findings involving full-length thymosin beta-4 should not be treated as direct clinical evidence for TB-500.
KPV: FDA reported no human exposure data at the time of review.
MOTS-c: Cell and animal findings exist alongside human physiology research and a registered clinical trial, but outcomes had not been posted at the time of review.
Epitalon: FDA reviewed preclinical findings, including telomerase and telomere-length effects in cultured human fibroblasts. FDA evaluated the proposed use of insomnia but did not identify published clinical studies evaluating effectiveness for that indication.
Emideltide (DSIP): PCAC did not recommend inclusion. FDA's briefing document identified insufficient evidence of effectiveness for the reviewed uses, no effectiveness data supporting the nominated subcutaneous route, and the availability of FDA-approved treatments for those conditions.
Clinicians discussing these substances with patients should be transparent about these evidence gaps. An advisory committee recommendation is not an endorsement of safety or efficacy — it is a procedural step toward potential compounding eligibility.
What This Does Not Mean
The coverage surrounding the July vote has generated significant confusion. The following distinctions are critical for physicians and patients:
1. This is not FDA approval. None of the six recommended peptides became an FDA-approved drug as a result of this vote. A PCAC recommendation is expert advice to the FDA Commissioner, nothing more.
2. The July vote did not establish compounding eligibility. A favorable PCAC recommendation, by itself, is not a legal basis for compounding the reviewed substances. Any compounding pharmacy or clinic claiming otherwise is getting ahead of the regulatory process.
3. Formal rulemaking is required. The FDA must review the committee's recommendations, publish a Notice of Proposed Rulemaking, accept public comments, and issue a final rule. Legal commentators (Orrick, Sheppard Mullin, Buchanan Ingersoll) have estimated that this process may take approximately 12–24 months based on historical precedent, but FDA has not committed to that timetable. The process could take longer, and a separate interim enforcement policy could alter the practical situation before a final rule.
4. Category 2 removal is not Category 1 placement. Removal from Category 2 after withdrawal of a nomination does not establish compounding eligibility or extend Category 1's interim enforcement-discretion policy to that substance. FDA continues to publish safety concerns for substances whose nominations were withdrawn.
What Is Still Pending
Four Peptides With Prior PCAC Review and Federal Litigation
AOD-9604, CJC-1295, ipamorelin acetate, and thymosin alpha-1 have been the subjects of prior PCAC review and federal litigation. FDA currently lists their withdrawn 503A nominations separately from the active Category 2 list — they are not in Category 2, but their removal does not establish compounding eligibility. Ipamorelin acetate separately remains in Category 2 under the 503B interim policy. The underlying lawsuit — Evexias Medical Centers, PLLC et al. v. United States FDA, No. 4:24-cv-00293, Northern District of Texas — has been filed and docketed. The current procedural status and any projected rulemaking timetable associated with it have not been independently verified from court filings for this article.
Next PCAC Meeting: Planned Before the End of February 2027
FDA has announced a second PCAC meeting before the end of February 2027 to review five additional peptides for the 503A Bulks List:
GHK-Cu — copper tripeptide complex. FDA's preliminary agenda names GHK-Cu without specifying the route. Non-injectable GHK-Cu was restored to Category 1 in May 2026; that status does not extend to injectable GHK-Cu.
Melanotan II — cyclic melanocortin-receptor agonist
Cathelicidin (LL-37) — host-defense peptide
Dihexa acetate — angiotensin IV-derived oligopeptide
PEG-MGF (Pegylated Mechano Growth Factor) — PEGylated IGF-1 splice variant fragment
A specific date has not yet been published. The FDA has stated that additional details and a public comment docket will follow.
The Category 1 Wildcard
There is one possible accelerator. FDA could consider a separate interim enforcement policy while rulemaking proceeds, though such a policy should not be assumed. Its January 2025 guidance stopped categorizing newly nominated substances submitted on or after January 7, 2025, while retaining the interim policy for existing Category 1 substances. Separately, Section 503A(c) of the FD&C Act permits regulations to be issued before advisory-committee consultation when necessary to protect public health — but that provision does not eliminate the regulatory requirement, and consultation on the seven July substances has already occurred. Whether the agency chooses to exercise any form of interim enforcement discretion remains an open question and one of the key developments to watch.
🔄 UPDATE — September 2026: As of September 17, 2026, the currently displayed 503A Bulks List (21 CFR 216.23, current through September 15, 2026) does not include BPC-157, TB-500, KPV, MOTS-c, Semax, or Epitalon. This review did not identify a published proposed rule adding these substances or an applicable peptide-specific interim policy extending enforcement discretion. The July advisory recommendations did not themselves establish compounding eligibility.
What This Means for Physicians
For physicians in integrative and functional medicine, the July PCAC vote represents a meaningful directional signal but not a green light. Until the FDA completes rulemaking, the legal landscape has not changed.
Physicians should:
Monitor the rulemaking timeline. When the FDA publishes a Notice of Proposed Rulemaking, there will be a public comment period. Physicians with clinical experience should consider submitting comments — real-world clinical observations are part of the record the FDA reviews.
Avoid premature claims. Do not advertise peptide therapies as "FDA-approved," "now legal to compound," or "coming soon" based on the advisory vote. State medical boards and the FTC apply their own standards, and marketing ahead of the regulatory process creates unnecessary exposure.
Educate patients carefully. Patients are reading the headlines. Many believe these peptides are now available through legitimate channels. Physicians have an opportunity — and an obligation — to provide accurate context about the regulatory timeline, the evidence gaps, and the risks of gray-market sourcing.
Prepare sourcing and compliance infrastructure. Physicians who anticipate offering peptide therapies once rulemaking concludes should begin evaluating state-licensed pharmacies operating under Section 503A. FDA-registered 503B outsourcing facilities operate under a separate regulatory framework with different requirements. In either case, verify that bulk drug substance APIs are sourced from FDA-registered manufacturing establishments with valid certificates of analysis.
Document clinical rationale. For any peptide use — current or anticipated — maintain thorough documentation of clinical reasoning, informed consent conversations, and the regulatory status at the time of prescribing.
Primary Sources and Further Reading
1. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Federal Register Docket: FDA-2025-N-6895.
2. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A. January 2025 (category-list updates issued separately, April 2026).
3. U.S. Food and Drug Administration. "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." (Current safety page listing withdrawn nominations and Category 2 substances.)
4. OpenLoop Health. "What Happened at the July Peptide PCAC Meeting and What's Next?" July 28, 2026.
5. McDermott Will & Schulte. "Bulk-List Bound? PCAC Backs Majority of Peptides in Two-Day Public Meeting." July 27, 2026.
6. Mintz. "FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do." July 29, 2026.
7. Buchanan Ingersoll & Rooney. "FDA Advisory Committee Voted Yes on Six Peptides. Now What? The Regulatory Road Ahead." August 2026.
8. LumaLex Law. "The July 2026 PCAC Peptide Meeting." July 25, 2026.
9. Frier Levitt. "FDA to Remove 12 Popular Peptides from the Category 2 'Do Not Compound' List." April 2026.
10. Orrick. "FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings." April 16, 2026.
11. Orrick. "FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting." July 21, 2026.
12. Goodwin. "FDA Signals Potentially Evolving Stance Toward Compounding of Certain Peptides." May 2026.
13. Sheppard Mullin. "What to Watch: Status Update on Peptide Regulation." June 15, 2026.
14. The FDA Law Blog (Hyman, Phelps & McNamara). "FDA's Pep(tide) Rally! What Compounders and Industry Need to Know." April 21, 2026.
15. Axios. "FDA Peptide Review Could Lead to New Compounding Boom." July 23, 2026.
16. Evexias Medical Centers, PLLC et al. v. United States FDA, No. 4:24-cv-00293, N.D. Tex. (docketed via Justia).
About the Author
Yoon Hang "John" Kim, MD, MPH is board-certified in Preventive Medicine and practices integrative and functional medicine. He is the author of eight books, including LDN Primer, LDN for Clinicians, MCAS: Epidemic in Plain Sight, and Integrative Oncology: Evidence-Based Strategies to Support Cancer Treatment. Dr. Kim completed a University of Arizona Osher Fellowship under Dr. Andrew Weil, holds the UCLA medical acupuncture certification, and is a recipient of the IFM Scholarship. He is the founder of the LDN Support Group.
Dr. Kim runs a membership-based telemedicine practice across six states and also practices at Hill Country Integrative Medicine in Fredericksburg, TX.
Learn more: directintegrativecare.com
⚠ DISCLAIMER: This article is for educational purposes only. It does not constitute legal advice, medical advice, or a recommendation to use, prescribe, or compound any peptide substance. The regulatory landscape is evolving. Verify all information against current FDA publications and consult a licensed healthcare attorney before making clinical or business decisions.
Remaining substantive corrections
Replace “approvals” and “overrode” with advisory language
The executive summary and July timeline still describe “six approvals” and say the committee “overrode” FDA staff. Those terms conflict with the article’s explanation that the votes were nonbinding recommendations.
Use this wording in both locations:
The committee recommended including six of the seven peptides on the 503A Bulks List, contrary to FDA staff recommendations against inclusion.
That accurately describes the reported outcome without suggesting that PCAC approved products or displaced FDA’s decision-making authority. FDA explicitly states that advisory-committee recommendations are nonbinding. (McDermott)
I would also delete “a historically unusual outcome” unless you specifically attribute that characterization and provide supporting historical comparisons.
Qualify the timeline in the executive summary—not just later
The detailed rulemaking section now appropriately qualifies the 12–24-month estimate, but the executive summary still presents it as an established timeline.
Replace the executive-summary paragraph with:
The PCAC vote is advisory. It is not rulemaking and does not itself establish compounding eligibility or grant FDA approval. Adding these substances to the 503A Bulks List would require FDA rulemaking. Legal commentators have estimated that the process could take approximately 12–24 months, but that estimate is not an FDA commitment or a guaranteed availability date.
Orrick’s July 21 article supports the estimate, while the statute establishes the regulatory-list pathway. Also avoid implying that FDA is obligated to adopt the favorable recommendations. (Orrick)
Remove the surviving “removed a prohibition” sentence
Your revised timeline addresses this correctly, but point 4 under “What This Does Not Mean” still says:
“Coming off Category 2 removed a prohibition.”
Replace point 4 with:
Category 2 removal is not Category 1 placement. Removal after withdrawal of a nomination does not establish compounding eligibility or extend Category 1’s interim enforcement-discretion policy to that substance.
Category 2 is an interim enforcement-policy classification, not a separate statutory prohibition that disappears when the entry is removed. FDA also continues to publish safety concerns for substances whose nominations were withdrawn. (U.S. Food and Drug Administration)
For the same reason, change “Category 2 of the interim 503A Bulk Drug Substances List” to “Category 2 under FDA’s interim 503A compounding policy.” In the 2023 paragraph, “were outside the Category 1 enforcement-discretion policy” is more defensible than “no longer within FDA’s enforcement tolerance,” which implies a previously established permissive status. (U.S. Food and Drug Administration)
Narrow “Nothing is legal to compound today” and revise the September update
The heading is broader than the supporting sentence beneath it. Your defensible point is that the July vote itself did not establish eligibility, not a universal statement about every peptide or compounding circumstance.
Replace the heading and paragraph with:
The July vote did not establish compounding eligibility. A favorable PCAC recommendation, by itself, is not a legal basis for compounding the reviewed substances.
FDA describes the recommendations as nonbinding; the governing statute separately specifies the bulk-substance requirements. (U.S. Food and Drug Administration)
For the September update, the current eCFR text I retrieved—displayed as updated through September 15, 2026—does not include the six recommended peptides. That establishes their absence from the codified list, but absence from the final list alone does not establish that no proposed rule exists. (eCFR)
Suggested update:
Update—September 17, 2026: The currently displayed 503A Bulks List does not include BPC-157, TB-500, KPV, MOTS-c, Semax, or Epitalon. This review did not identify a published proposed rule adding these substances or an applicable peptide-specific interim enforcement policy. The July advisory recommendations did not themselves establish compounding eligibility.
The first sentence is directly verifiable from the regulation. The second should remain explicitly framed as a search finding, not a categorical guarantee that no publication exists. (eCFR)
Also replace “interim enforcement policy authorizing compounding” with “interim policy extending enforcement discretion.” Enforcement discretion and statutory authorization are not interchangeable. (U.S. Food and Drug Administration)
Revise “The Category 1 Wildcard”
The public-health exception changes the timing of consultation, not the requirement for a regulation. Its relevance to the July substances is limited because consultation has already occurred. That last point is a procedural inference from the statute and the completed meeting. (Legal Information Institute)
Replace the paragraph with:
FDA could consider a separate interim enforcement policy while rulemaking proceeds, but such a policy should not be assumed. Its January 2025 guidance stopped categorizing newly nominated substances submitted on or after January 7, 2025, while retaining the interim policy for existing Category 1 substances. Separately, Section 503A(c) permits regulations to be issued before advisory-committee consultation when necessary to protect public health. That provision does not eliminate the regulatory requirement, and consultation on the seven July substances has already occurred.
This also corrects “guidelines” to “guidance” and avoids presenting restoration to Category 1 as the only possible enforcement-policy mechanism. (U.S. Food and Drug Administration)
Correct the next-meeting heading and clarify GHK-Cu
The body says “before the end of February 2027,” but the heading still says “Before February 2027.” FDA’s announcement uses before the end of February 2027 and has not specified a date, time, or location on the page reviewed. (U.S. Food and Drug Administration)
Use this heading:
Next PCAC Meeting: Planned Before the End of February 2027
FDA’s preliminary agenda lists GHK-Cu, not an expressly injectable-only review. Therefore, remove “(injectable)” from the agenda item unless a subsequent notice specifically limits the scope. (U.S. Food and Drug Administration)
Suggested GHK-Cu entry:
GHK-Cu — copper tripeptide complex. FDA’s preliminary agenda names GHK-Cu without specifying the route. Non-injectable GHK-Cu was restored to Category 1 in May 2026; that status should not be extrapolated to injectable GHK-Cu.
The May 14 FDA update explicitly documents the restoration of “GHK-Cu (except for injectable routes of administration).”
Tighten the Emideltide and Epitalon evidence statements
Emideltide: The phrase “panelists cited” requires a meeting record or identifiable contemporaneous account. FDA briefing documents establish FDA’s analysis, not necessarily each panelist’s reasons. Furthermore, withdrawn nominations were not unique to Emideltide.
Suggested replacement:
Emideltide (DSIP): PCAC did not recommend inclusion. FDA’s briefing document identified insufficient evidence of effectiveness for the reviewed uses, no effectiveness data supporting the nominated subcutaneous route, and the availability of FDA-approved treatments for those conditions.
That separates the committee outcome from FDA’s documented rationale. (McDermott)
Epitalon: “Small pilot data” remains too vague without an identifiable study. FDA’s telomere discussion describes experiments in cultured human fibroblasts, which should not be presented as demonstrated telomere lengthening in treated patients.
Suggested replacement:
Epitalon: FDA reviewed preclinical findings, including telomerase and telomere-length effects in cultured human cells. It evaluated the proposed use of insomnia but did not identify published clinical studies evaluating effectiveness for that indication.
This preserves the distinction between mechanistic findings and clinical outcomes.
Final formatting and sourcing cleanup
The table header is still merged into one cell, and its source note introduces “Clinical Peptide” without a matching bibliographic entry.
Location | Final edit |
Table headings | Use four separate columns: Peptide, Uses evaluated by FDA, Vote—yes/no/abstentions, PCAC recommendation. |
DSIP result | Change REJECTED to NOT RECOMMENDED FOR INCLUSION to avoid suggesting a final FDA determination. |
Table scope | Add: “The votes concerned the reviewed free-base and acetate forms. The listed uses are not FDA-approved indications.” FDA’s agenda identifies these forms and reviewed uses. (U.S. Food and Drug Administration) |
Table source note | Attribute vote counts to the verified McDermott meeting report; attribute reviewed uses to FDA’s agenda. Add a complete “Clinical Peptide” reference or remove that citation. (McDermott) |
Litigation heading | Change “Prior PCAC Review and Ongoing Litigation” to “Prior PCAC Review and Federal Litigation” because the paragraph expressly says current procedural status was not verified. |
The MOTS-c registry claim should include its study identifier and the date its results status was checked. I could not independently reload the registry’s results fields during this pass, so I would not label that detail freshly verified. FDA’s briefing document itself reports no published studies involving human administration of the reviewed MOTS-c substances.
The remaining unverified items are the lawsuit’s current status, the MOTS-c registry’s current results status, and the author biography. I also have not revalidated every secondary bibliography entry in this pass. The substantive corrections above address the remaining wording that could misstate the regulatory process or overstate what the cited evidence establishes.
Comments